Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00095745 · ClinicalTrials.gov registry record · Phase 3

A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder

A Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.

Completed
Registry status
Phase 3
Development phase
1,002
Enrollment target

NCT00095745: Completed Phase 3 study, sponsored by Otsuka Pharmaceutical Development & Commercialization.

NCT00095745 is a Phase 3 study that has completed, run by Otsuka Pharmaceutical Development & Commercialization. The registered enrollment target is 1,002 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00095745, a Phase 3 study, has completed, sponsored by Otsuka Pharmaceutical Development & Commercialization.

COMPLETED
Registry status
Phase 3
Development phase
1,002 participants
Enrollment target

Study Summary

This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

Interventions

  • DRUG Antidepressant + Aripiprazole

Trial Details

FieldValue
Enrollment Target 1,002 participants
Start Date 2004-09
Est. Completion 2007-11
Phase Phase 3

What the finished NCT00095745 record still lists

NCT00095745 is an interventional study that assigns participants to a tested intervention. Its 1,002 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).

The record links to 0 conditions, and to 1 intervention - of which Antidepressant + Aripiprazole is the first listed.

NCT00095745 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00095745 about?

NCT00095745 is a clinical study titled "A Long-Term Study of Aripiprazole in Patients With Major Depressive Disorder". This trial is a 52-week safety study to evaluate the safety of adjunctive aripiprazole in outpatients with major depressive disorder who have experienced an incomplete response to an ongoing antidepressant trial.

What is the current status of trial NCT00095745?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,002 participants. The study started on 2004-09. Estimated completion is 2007-11.

What interventions are being tested in trial NCT00095745?

The interventions under investigation include: Antidepressant + Aripiprazole (DRUG).

Who is sponsoring clinical trial NCT00095745?

This trial is sponsored by Otsuka Pharmaceutical Development & Commercialization, which has 221 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00095745's enrollment target sits among peer trials

1,002 295th of 2000 higher than 1,706 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06207864 · 1,001 participants · NA

    Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00095745, the US trial registry maintained by the National Library of Medicine. NCT00095745 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.